US Patent Issued to STALICLA on Nov. 18 for "Metabolic profiling for the diagnosis of a subset of idiopathic autism spectrum disorder patients, ADS Phenotype 1" (Swiss Inventors)

ALEXANDRIA, Va., Nov. 18 -- United States Patent no. 12,474,327, issued on Nov. 18, was assigned to STALICLA SA (Geneva).

"Metabolic profiling for the diagnosis of a subset of idiopathic autism spectrum disorder patients, ADS Phenotype 1" was invented by Lynn Durham (Geneva) and Jean-Marc Hyvelin (Geneva).

According to the abstract* released by the U.S. Patent & Trademark Office: "The invention relates to a method of diagnosing a subtype of autism spectrum disorder (ASD), so called ASD Phenotype 1, by assessing the energy production capacity of patient specific cell lines in presence of various carbon sources of energy and metabolic factors or by assessing the changes in energy production capacity or lack thereof after administration of a...